FREMONT, Calif., May 29, 2018 /PRNewswire/ -- Ardelyx, Inc.
(NASDAQ: ARDX) today announced that Mike
Raab, president and chief executive officer of Ardelyx, will
present a company overview at the Jefferies Global Healthcare
Conference on Tuesday, June 5, 2018
at 2:30 p.m. ET in New York City.
To access the live webcast of Ardelyx's presentation please
visit the Events & Presentations page within the Investor
section of the Ardelyx website at ir.ardelyx.com. A replay of the
webcast will be available on the Ardelyx website for 60 days
following the conference.
About Ardelyx, Inc.
Ardelyx is focused on
enhancing the way people with renal diseases are treated by
developing first-in-class medicines. Ardelyx's renal
pipeline includes the Phase 3 development of tenapanor for the
treatment of hyperphosphatemia in people with end-stage renal
disease who are on dialysis and RDX013, a potassium secretagogue
program for the potential treatment of high potassium, or
hyperkalemia, a problem among certain patients with kidney and/or
heart disease. In addition, Ardelyx has completed Phase 3
development of tenapanor for the treatment of irritable bowel
syndrome with constipation and anticipates submitting a New Drug
Application to the U.S. Food and Drug Administration for
this indication in the second half of 2018. To efficiently bring
its treatments to market, Ardelyx is pursing strategic
collaborations in the U.S. and other countries, including
through established agreements with Kyowa Hakko
Kirin in Japan, Fosun Pharma
in China and Knight
Therapeutics in Canada. For more information, please
visit www.ardelyx.com/ and connect with us on Twitter
@Ardelyx.
View original content with
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-2018-global-healthcare-conference-300655532.html
SOURCE Ardelyx